David James Ballance is VP & Research and Sci. Affairs at PhaseBio Pharmaceuticals Inc (PHAS). They have made 1 open-market trade across 1 company since 2018, most recently 2020-11-20.
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $4K since 2018, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| PHAS | 8,519 | $597 |
Shares reported on the most recent Form 4, priced at the 2020-11-23 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| PHAS | BUY | 2018-12-13 | 2018-12-17 | $3.94 | $4K | -18.2% | +0.5% | +67.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.